Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

Inclusion Criteria:

1. Patients with histologic confirmation of invasive, but non-inflammatory carcinoma of
the breast.

2. Stage I (T1N0) are not eligible for the neo-adjuvant portion of the protocol.

3. High-risk patients (patients with any of the following: high proliferation rate -
Ki67 >35% or poorly differentiated tumors (black's modified grade 3); ER/PR negative;
lymphovascular invasion) with stage I disease are eligible for adjuvant therapy.

4. Patients with pure mucinous carcinomas, tubular carcinomas or pure medullary
carcinomas are eligible if the patient's tumor is larger than 3 cm in size or if the
patient has tumor involvement of the lymph nodes (>2mm).

5. Patients with bilateral breast cancers are eligible.

6. Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as
are patients with pN3a (ten or more axillary lymph nodes). Patients with
infraclavicular lymph node involvement are NOT eligible.

7. Patients must have clinically measurable disease to be treated in the neoadjuvant
setting. This includes patients with a non-palpable primary who have histologically
proven lymph node (LN) involvement that is clinically palpable and measurable by
ultrasound

8. Histologic confirmation of invasive tumor will be done by core needle biopsy for
patients with intact primary tumors. If patients have undergone adequate core biopsy
prior to evaluation at MDACC, repeat core biopsy is optional.

9. Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study, in keeping with institutional policy.

10. Patients with a prior history of breast cancer are eligible if the current primary
breast cancer is of a higher stage than the original breast cancer and the patient
has not received any of the current study medications including past doxorubicin.

11. Patients should have adequate bone marrow function, as defined by peripheral
granulocyte count of > 1,500/mm3, and platelet count > 100,000/mm3. Patients must
have adequate liver function with a bilirubin within normal laboratory values.
Transaminases (SGPT) may be up to 2.5x upper limit of normal (ULN) if alkaline
phosphatase is < ULN or alkaline phosphatase may be up to 4 x ULN if transaminases
are < ULN.

12. In addition, patients should have adequate renal function, defined as a serum
creatinine < 2.5 mg% and/or creatinine clearance greater than 51 ml/min as calculated
by Cockcroft and Gault Equation: Cockcroft and Gault Equation: Creatinine clearance
for males = {(140 - age [yrs])(body weight [kg])}/{(72) (serum creatinine [mg/dL])}.
Creatinine clearance for females = 0.85 x male value

13. Patients who had surgical therapy prior to referral will be eligible for
randomization to systemic chemotherapy administered in the adjuvant setting.

14. Patients who have overexpression of the her-2/neu oncogene are eligible for the
study.

Exclusion Criteria:

1. Patients with N2 (clinical staging) or N3 (clinical staging) nodal disease,
inflammatory breast cancer, or metastatic disease are not eligible. This includes
patients with infraclavicular and/or supraclavicular lymph node involvement. Patients
with pN2a (metastasis in four to nine axillary lymph nodes) are eligible.

2. Patients with pN2b (metastasis in clinically apparent internal mammary lymph nodes in
the absence of axillary lymph node metastasis) are not eligible. Patients with T4
lesions in the neoadjuvant setting are not eligible. Patients with limited T4 lesions
in the adjuvant setting (for example, focal extension into the skin with negative
margins) are eligible.

3. Severe hypersensitivity reactions to agents formulated in either cremophor or
polysorbate 80 must be excluded. Patients with hypersensitivity reactions to any of
the study medications must be excluded.

4. Those patients with history of other malignancies will be excluded, except
non-melanoma skin cancer and non-invasive cervical cancer.

5. Patients with uncompensated congestive heart failure are not eligible. Patients with
myocardial infarction within the past 12 months are ineligible.

6. Patients who are pregnant or lactating are not eligible. Women of childbearing
potential must have a negative pregnancy test prior to initiation of chemotherapy.
Women of childbearing potential who will not use a reliable and appropriate
contraceptive method during the study are not eligible.

7. Patients who have had an organ allograft are ineligible.

8. Patients with serious concurrent infections are ineligible.

9. Sexually active male patients unwilling to practice contraception during the study
are ineligible.

10. Patients with pre-existing peripheral neuropathy > grade 1.